Trastuzumab Deruxtecan

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By MedXY 10/31/2025

Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.

Internal Medicine Oncology Specialties

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib

By MedXY 10/18/2025

This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.

Oncology Specialties

Enhancing Quality of Life in ERBB2-Positive Metastatic Breast Cancer: The PRO-DUCE Trial on Electronic Symptom and Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy

By MedXY 09/11/2025

The PRO-DUCE randomized trial demonstrates that electronic symptom and vital sign monitoring during trastuzumab deruxtecan therapy can preserve quality of life in ERBB2-positive metastatic breast cancer patients, with notable improvements in functional outcomes and fatigue management.

Clinical Updates news Oncology

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY 09/08/2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemotherapy.

news Oncology Specialties

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.